National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Inotersen (Tegsedi®). HTA ID: 19034

Inotersen (Tegsedi®) is indicated for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).

 

NCPE Assessment Process Complete
Rapid review commissioned 26/08/2019
Rapid review completed 07/10/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 09/10/2019
Pre-submission consultation with Applicant 08/12/2020
Full HTA submission received from Applicant 23/07/2021
Preliminary review sent to Applicant 05/10/2021
NCPE assessment re-commenced 02/11/2021
Factual accuracy check sent to Applicant 22/12/2021
NCPE assessment re-commenced 10/01/2022
NCPE assessment completed 11/02/2022
NCPE assessment outcome The NCPE recommends that inotersen be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.